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Blood-based analysis of type-2 
diabetes mellitus susceptibility 
genes identifies specific transcript 
variants with deregulated 
expression and association with 
disease risk
Maria-Ioanna Christodoulou1,2,3, Margaritis Avgeris  1, Ioanna Kokkinopoulou1, 
Eirini Maratou2, Panayota Mitrou2, Christos K. Kontos  1, Efthimios pappas2, Eleni Boutati4, 
Andreas Scorilas  1 & Emmanuel G. Fragoulis1
Despite significant progress by genome-wide association studies, the ability of genetic variants to 
conduce to the prediction or prognosis of type-2 diabetes (T2D) is weak. Expression analysis of the 
corresponding genes may suggest possible links between single-nucleotide polymorphisms and T2D 
phenotype and/or risk. Herein, we investigated the expression patterns of 24 T2D-susceptibility genes, 
and their individual transcript variants (tv), in peripheral blood of T2D patients and controls (CTs), 
applying RNA-seq and real-time qPCR methodologies, and explore possible associations with disease 
features. Our data revealed the deregulation of certain transcripts in T2D patients. Among them, 
the down-regulation of CAPN10 tv3 was confirmed as an independent predictor for T2D. In patients, 
increased expression of CDK5 tv2, CDKN2A tv3 or THADA tv5 correlated positively with serum insulin 
levels, of CDK5 tv1 positively with % HbA1c levels, while in controls, elevated levels of TSPAN8 were 
associated positively with the presence of T2D family history. Herein, a T2D-specific expression profile 
of specific transcripts of disease-susceptibility genes is for the first time described in human peripheral 
blood. Large-scale studies are needed to evaluate the potential of these molecules to serve as disease 
biomarkers.
Type-2 diabetes mellitus (T2D), a chronic metabolic disorder with increased cardiovascular morbidity and mor-
tality, accounts currently for one of the global epidemics with ever growing prevalence1. Despite recent advances 
in T2D diagnosis and management, challenges in its prevention and treatment still remain2.
T2D epidemic is mainly ascribed to the continuous increase in obesity globally, favored nowadays by the 
adoption of a sedentary lifestyle2, while the risk for T2D development depends also on genetic components. 
During the last decade, over 60 genome-wide association studies (GWAS) revealed more than 250 single nucle-
otide polymorphisms (SNPs) related to T2D or glycemic traits3. However, each of them individually increases 
disease risk with rather modest effect sizes (25–40% increase in the homozygous state for the genes conveying the 
greatest risk)4, which are further weakened when introduced in multivariate analysis models5.
The implication of the genome in the development of human disorders can be elucidated through the study of 
the transcriptome, given that the last reflects functionality6–9. Recent advances in transcriptome analysis provide 
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key-data for (i) the link between genotype and phenotype, (ii) molecular networks underlying pathophysiological 
processes, and (iii) molecular fingerprints, paving the way for the identification of possible therapeutic targets 
and/or disease biomarkers7,10. Next-generation RNA-sequencing (RNA-Seq) has pivotally fashioned the mode of 
transcriptome profiling, giving the chance for gene-transcription levels and splicing isoforms to be detected and 
quantitated, in a high-throughput manner7,11,12.
The gene-expression signature of T2D, including the expression patterns of T2D-susceptibility genes, has been 
hardly investigated. Previous studies were confined to pancreatic islets or beta-cell lines from animal models or 
deceased human donors13, mainly due to difficulties in obtaining biopsy specimens from the T2D-target tissue(s) 
of living donors. However, recent evidence support that the gene-expression profile of peripheral blood cells 
reflects significantly (>80%) the gene-expression profile of other tissues, including disease-affected tissues, and 
that changes in the former mirror changes in the micro- and macro-environment of the latter14. Thus, peripheral 
blood is considered as a reliable alternative for the investigation of transcriptome dynamics of organ-specific and 
systemic diseases, as it is easily accessible, and provides data for pathophysiological processes taking place in 
various sites throughout the human body15.
Herein, we investigated the expression patterns of highly-related T2D-susceptibility genes in peripheral blood 
samples of patients and controls and explored possible associations with disease parameters and risk factors.
Materials and Methods
Study design. First, we developed a panel of highly-associated T2D-susceptibility genes. For the quantifica-
tion of their expression, appropriate reverse transcription (RT) - real-time PCR (qPCR) protocols were developed 
and applied on RNA extracted from whole peripheral blood samples of T2D patients and controls (CT). RNA-Seq 
and specific qPCR protocols were utilized to identify specific transcript variants of these genes that are differen-
tially expressed between the two groups. To examine specific distribution patterns in individuals at high risk of 
developing the disease, a distinct group of controls bearing T2D-risk factors was included in the total group of 
controls. The two subgroups were analyzed both together and separately. Finally, possible associations between 
the gene or transcript-variant expression levels and various disease parameters were explored.
Development of the T2D-susceptibility gene panel. The 24 highly-associated T2D-susceptibility gene 
panel was developed upon in-depth search in the NHGRI-EBI Catalog of published GWAS and SNPedia online 
databases3,16 (Table 1). CAPN10 is not included in GWAS-significant genes, however, in SNPedia it presents as 
carrying variants related to T2D in different populations, and thus it was included in the panel. CDK5 was also 
included, since it is highly regulated by the T2D-susceptibility gene CDKAL117.
Patients and samples. Peripheral blood samples were collected from 48 consecutive T2D patients and 
40 control (CT) individuals (with normal glucose metabolism), upon informed written consent. The study was 
approved by the Ethics Committee of the Attikon Hospital (Athens, Greece). Both groups were characterized 
according to the current criteria for T2D diagnosis18. The medical records of the participants were evaluated for 
various clinical, laboratory, and therapeutic variables. The group of controls consisted of two distinct subgroups: 
controls without risk factors for the development of T2D (CTRF−; n = 17) and controls bearing risk factors for the 
disease (CTRF+; n = 23), as these were previously described by Nathan2 (Table 2).
RNA extraction, RT-qPCR and RNA-seq. All the methods used for gene-expression analysis, were 
applied on RNA extracted from whole peripheral blood using direct-blood lysis. For materials and protocols 
applied for RNA extraction, reverse transcription, and qPCR, as well as cDNA library construction and RNA-seq, 
see Supplemental Fig. 1. Specific primers designed for the amplification of the genes-of-interest, or certain tran-
script variants of them are reported in Supplemental Table 1. Relative quantification (RQ) of gene expression was 
performed by the 2−ΔΔCt method, using the hypoxanthine phosphoribosyltransferase 1 (HPRT1) gene, as endog-
enous reference gene for normalization purposes, and the immortalized 1.2B4 pancreatic beta-cell line (ECACC, 
Salisbury, UK), as our assay calibrator, for the calculation of the fold-changes. Representative amplification, melt-
ing and standard curves for certain genes/transcript variants are indicatively presented in Supplemental Fig. 2.
Bioinformatics analysis. For analysis of RNA-seq raw data see Supplemental Fig. 1. Differential expression 
between the two groups was considered significant if fold-change of their average RPKMs (CT:T2D ratio) was 
<0.5 or >2. Area-proportional Euler diagrams were generated using the BioVenn tool (http://www.biovenn.nl/). 
Analysis of tissue-specific expression patterns of genes and transcript variants and expression quantitative trait 
loci (eQTLs) was performed utilizing the portal of the Genotype-Tissue Expression (GTEx) project19 and the 
Blood eQTL browser20.
Statistical analysis. Differential expression patterns between CT and T2D, or among CTRF−, CTRF+, and 
T2D individuals, were explored using the non-parametric Mann–Whitney U or Jonckheere-Terpstra tests, 
respectively. Benjamini-Hochberg procedures for adjusting the false discovery rate (FDR = 0.25) in multi-
ple comparisons were also applied. Possible associations with binary, ordinal or continuous values of various 
clinicopathological and laboratory parameters were investigated by Mann-Whitney U, Jonckheere-Terpstra, or 
Spearman’s rank correlation coefficient tests, respectively. Binomial multivariate logistic regression analysis was 
performed (enter model) using the occurrence of T2D as the dependent variable and the expression levels of 
genes and transcript variants, age and sex as independent variables. Analyses were performed using the soft-
wares: GraphPad Prism 5 (GraphPad Software Inc., San Diego, CA, USA) or IBM SPSS Statistics 21 (IBM Corp., 
Armonk, NY, USA). P-values < 0.05 were considered significant.
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Gene symbol Gene name
Chromosomal 
region SNP
No of CS/GWAS 
report significance p-value min p-value max
ADAMTS9 ADAM metallopeptidase with thrombospondin type 1 motif 9 3p14.1 rs4607103 1 1.00e-08 —
CAPN10 Calpain 10 2q37.3
rs3792267 4 3.00e-03 3.00e-02
2 1.00e-02 3.00e-02
rs5030952 1 5.00e-02 —
CDC123/CAMK1D Cell division cycle 123/ calcium/calmodulin dependent protein kinase ID 10p13
rs10906115 1 1.00e-08
rs12779790 1 1.00e-10
rs11257655 3 1.00e-12 7.00e-09
CDKAL1 CDK5 regulatory subunit associated protein 1 like 1 6p22.3
rs7766070 4 2.00e-11 9.00e-09
rs7754840 4 2.00e-13 7.00e-10
rs7756992 2 1.00e-16 8.00e-09
rs10946398 2 1.00e-08 7.00e-07
rs4712523 1 7.00e-20 —
rs6931514 1 1.00e-11 —
rs4712524 1 3.00e-10 —
rs10440833 1 2.00e-22 —
rs9295474 1 9.00e-06 —
rs35612982 1 6.00e-36 —
rs9465871 1 3.00e-07 —
CDKN2A/CDKN2B Cyclin dependent kinase inhibitor 2A/cyclin dependent kinase inhibitor 2B 9p21.3
rs2383208 1 2.00e-29 —
rs10811661 6 1.00e-27 5.00e-06
rs564398 1 1.00e-06 —
rs1333051 1 6.00e-10 —
rs7020996 1 2.00e-07 —
rs10965250 1 1.00e-10 —
rs2383208 2 5.00e-33 3.00e-06
CDK5 Cyclin-dependent kinase 5 Regulated by CDKAL1
FTO FTO, alpha-ketoglutarate dependent dioxygenase 16q12.2
rs9939609 2 1.00e-20 2.00e-07
rs8050136 5 2.00e-17 7.00e-06
rs11642841 1 3.00e-08 —
rs9936385 1 1.00e-12 —
rs1421085 1 4.00e-15 —
HHEX Hematopoietically expressed homeobox 10q23.33
rs5015480 5 1.00e-15 9.00e-06
rs1111875 6 3.00e-19 3.00e-06
rs78627331 1 2.00e-14 —
rs34773007 1 2.00e-14 —
rs7087591 1 6.00e-20 —
HNF1B HNF1 homeobox B 17q12
rs4430796 4 2.00e-11 4.00e-06
rs10908278 1 4.00e-15 —
HNF4A Hepatocyte nuclear factor 4 alpha 20q13.12
rs4812829 2 3.00e-10 5.00e-08
rs6017317 1 1.00e-11 —
IGF2BP2 Insulin-like growth factor 2 mRNA-binding protein 2 3q27.2
rs4402960 7 1.00e-17 1.00e-06
rs1374910 1 1.00e-07 —
rs1470579 8 2.00e-24 5.00e-06
rs138306797 1 3.00e-06 —
rs6769511 1 1.00e-09 —
rs11927381 1 3.00e-14 —
JAZF1 JAZF zinc finger 1 7p15.1
rs864745 1 5.00e-14 —
rs849134 2 6.00e-13 3.00e-09
rs849135 1 2.00e-09 —
KCNQ1 Potassium voltage-gated channel subfamily Q member 1 11p15.4
rs2237892 5 2.00e-14 4.00e-06
rs163182 1 2.00e-17 —
rs2237895 1 1.00e-09 —
rs2237897 2 1.00e-16 9.00e-15
rs231362 1 3.00e-13 —
rs2283228 2 5.00e-13 1.00e-10
rs231356 1 4.00e-08 —
rs8181588 1 5.00e-09 —
rs163184 1 2.00e-14 —
rs2237896 1 3.00e-70 —
rs117601636 1 1.00e-07 —
Continued
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Statement of Ethical Approval and Informed Consent. The study was approved by the Ethics 
Committee of the Attikon Hospital (Athens, Greece). All procedures followed were in accordance with the ethical 
standards of the responsible committee on human experimentation (institutional and national) and with the 
Helsinki Declaration of 1975, as revised in 2008 (5). Informed consent was obtained from all patients for being 
included in the study.
Results
Differential expression of certain T2D-susceptibility genes in patients versus controls. Firstly, 
specifically designed qPCR protocols applied on RNA extracted from whole peripheral blood samples, detected 
quantifiable expression levels in the cases of the following 20 genes: CAMK1D, CAPN10, CDC123, CDK5, 
CDKAL1, CDKN2A, CDKN2B, FTO, HHEX, IGF2BP2, JAZF1, KCNJ11, KCNQ1, NOTCH2, PPARG, SLC30A8, 
TCF7L2, THADA, TSPAN8 and WFS1. On the contrary, mRNA expression was not detected in samples of either 
patients or controls, in the cases of ADAMTS9, HNF1B, HNF4A and MTNR1B genes.
Relative quantification (RQ) values (median; range) in the groups of T2D patients (n = 48) and controls 
(n = 40) are summarized in Table 3. Mann-Whitney U test revealed that compared to controls, T2D patients 
expressed significantly higher levels of the genes CDK5 [p = 0.0056, RQ values (median; range) for T2D = 1.151 
(0.600–8.103) and for CT = 0.945 (0.512–2.473), fold-change T2D vs. CT = 1.22], CDKN2A [p = 0.0411, RQ 
values (median; range) for T2D = 0.910 (0.320–4.030) and for CT = 0.655 (0.150–2.420), fold-change T2D vs. 
CT = 1.39] and TSPAN8 [p = 0.0055, RQ values (median; range) for T2D = 0.234 (0.0398–2.124) vs. CT = 0.159 
(0.0247–1.132), fold-change T2D vs. CT = 1.47] (Table 3 and Fig. 1A; upper row). Further analysis within the 
group of CTs, revealed that CTRF+ individuals (n = 23) were characterized by elevated levels of the three above-
mentioned genes compared to CTRF− (n = 17) ones (Table 3 and Fig. 1A; lower row). Jonckheere-Terpstra test 
further confirmed this increase, revealing a gradual up-regulation in the mRNA levels of these genes among 
the groups of CTRF−, CTRF+ and T2D subjects [as for the CDK5 gene: p = 0.009, RQ values (median; range) for 
CTRF− = 0.919 (0.625–2.473), for CTRF+ = 1.005 (0.512–1.998) and for T2D = 1.151 (0.600–8.103), fold-change 
for CTRF+ vs. CTRF− = 1.09 and for T2D vs. CTRF+ = 1.15; as for the CDKN2A gene: p = 0.010, RQ values (median; 
range) for CTRF− = 0.426 (0.200–2.220), for CTRF+ = 0.920 (0.150–2.420) and for T2D = 0.910 (0.320–4.030), 
fold-change for CTRF+ vs. CTRF− = 2.16 and for T2D vs. CTRF+ = 0.99; as for the TSPAN8 gene: p = 0.001, RQ val-
ues (median; range) for CTRF− = 0.1071 (0.0247–1.132), for CTRF+ = 0.1894 (0.0741–0.832) and for T2D = 0.2340 
(0.0398–2.124), fold-change for CTRF+ vs. CTRF− = 1.77 and for T2D vs. CTRF+ = 1.24) (Table 3 and Fig. 1A; lower 
row). Statistics for all comparisons are reported in Table 3. After applying correction for multiple comparisons, 
the differential expression patterns that remained significant were those of: CDK5 and TSPAN8 between CT and 
T2D groups, and of CDK5, CDKN2A and TSPAN8 among the CTRF−, CTRF+ and T2D groups.
RNA-Seq analysis. Following the quantification of the expression levels of the abovementioned 20 genes, 
we studied also the expression patterns of their individual transcript variants in order to: (i) detect the specific 
transcript variant(s) responsible for the aforesaid differences and (ii) reveal any possible “hidden” differences in 
Gene symbol Gene name
Chromosomal 
region SNP
No of CS/GWAS 
report significance p-value min p-value max
KCNJ11 Potassium voltage-gated channel subfamily J member 11 11p15.1
rs5215 3 3.00e-11 4.00e-07
rs5219 4 7.00e-11 5.00e-07
MTNR1B Melatonin receptor 1B 11q14.3
rs1387153 1 8.00e-15 —
rs10830963 1 2.00e-07 —
NOTCH2 Neurogenic locus notch homolog protein 2 1p12 rs10923931 1 4.00e-08 —
PPARG Peroxisome proliferator activated receptor gamma 3p25.2
rs1801282 4 6.00e-10 2.00e-06
rs17036101 1 2.00e-07 —
rs13081389 1 2.00e-07 —
SLC30A8 Solute carrier family 30 member 8 8q24.11
rs13266634 10 2.00e-14 7.00e-06
rs3802177 3 2.00e-18 4.00e-08
TCF7L2 Transcription factor 7 like 2 10q25.2
rs7903146 24 4.00e-94 5.00e-08
rs7901695 2 1.00e-48 1.00e-06
rs34872471 3 6.00e-53 8.00e-08
rs4506565 1 5.00e-12 —
THADA THADA, armadillo repeat containing 2p21 rs7578597 1 1.00e-09 —
TSPAN8 Tetraspanin 8 12q21.1
rs7961581 1 1.00e-09 —
rs4760790 1 4.00e-06 —
rs1495377 1 7.00e-06 —
WFS1 Wolframin ER transmembrane glycoprotein 4p16.1
rs1801214 1 3.00e-08 —
rs4458523 1 2.00e-09 —
Table 1. T2D-susceptibility genes selected to be investigated in the current study, upon search in NHGRI-EBI 
Catalog of published GWAS and SNPedia online databases. Annotations for the most highly T2D-associated 
SNPs in each gene, number of large-scale clinical (CS) or genome-wide association studies (GWAS) describing 
significant association of each SNP with the disease, as well as minimum and maximum p-values reported 
among studies, are stated (in the case of SNPs described in only one study, a sole p-value is stated).
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the levels of specific variants of the rest 17 genes, in patients versus controls. For that reason, data from RNA-Seq 
performed on peripheral blood samples of representative T2D patients (n = 4) and controls (n = 2) were analyzed 
appropriately.
Focusing on the 24 genes-of-interest, T2D patients were found to express: (i) higher levels of the genes 
CAPN10, KCNQ1 and TCF7L2 and of the transcripts NM_023085 (CAPN10), NM_000218 (KCNQ1), 
NM_001198530, NM_001146284, NM_001198527 (all of TCF7L2), NR_073394 (THADA) (Fig. 1B and 
Supplemental Table 2) and (ii) and lower levels of the genes CDKAL1 and IGF2BP2 and of the transcripts 
NM_017774 (CDKAL1), NM_001291873, NM_001291872, NM_001291875 (all of IGF2BP2), NM_001271643, 
NM_001271644, NM_001083953, NM_022065 (all of THADA) (Fig. 1B and Supplemental Table 2), compared 
to controls.
Features CT (n = 40) T2D (n = 48)
General
Age (years); median (range) 50 (19–69) 60 (35–77)
Sex (male/female); number (%) 21/19 (53/47) 27/21 (56/44)
Disease duration (years); median (range) NA 5 (0–26)
Family history (yes/no); number (%) 16/24 (40/60) 34/14 (71/29)
Risk factors* (presence/absence); number (%) 23/17 (57/43) NA
Anthropometric
BMI (body mass index)†; median (range) 27.0 (21.3–36.3)
29.5 
(21.5–46.5)
   <25: normal weight; number (%) 18 (45) 7 (15)
   25–30: overweight; number (%) 14 (35) 19 (41)
   >30: obese; number (%) 8 (20) 22 (46)
W/H (waist-to-hip ratio); median (range) 0.90 (0.71–1.09)
0.93 
(0.83–1.18)
Central obesity‡ (yes/no); number (%) 15/25 (38/62) 43/5 (90/10)
Clinical
Hypertension§ (yes/no); number (%) 5/35 (13/87) 29/19 (60/40)
Hyperlipidemia‖ (yes/no); number (%) 8/32 (20/80) 37/11 (77/23)
Metabolic syndrome¶ (yes/no); number (%) 6/34 (15/85) 37/11 (77/23)
Laboratory
HbA1c levels (% or mmol/ml); median (range) 5.6 (4.9–6.1) 6.6 (5.2–12.1)
   <7% or 53; number (%) 40 (100) 33 (69)
   ≥7% or 53; number (%) 0 (0) 15 (31)
Glucose levels (mg/dl); median (range) 85 (68–120)
   <130; number (%) 40 (100) 29 (60)
   ≥130; number (%) 0 (100) 19 (40)
Insulin levels (μU/ml); median (range) 9.4 (5.2–19.1) 13.7 (3.8–56.0)
Cholesterol levels (mg/dl); median (range)
   Total cholesterol 199 (109–281) 184 (119–256)
   High-density cholesterol (HDL) 49 (6–79) 41 (17–125)
   Low-density cholesterol (LDL) 122 (19–192) 113 (53–191)
Triglycerides levels (mg/dl); median (range) 114 (65–176) 147 (79–363)
T2D therapy
Naïve (prior to treatment); number (%) NA 8 (16.7)
Tablets (metformin, vildagliptin, glimeripide, gliclazide); number (%) NA 22 (45.8)
Two tablets (metformin + glimepiride, metformin + vildagliptin); or 
one tablet (metformin) + injectable GLP-1 (liraglutide) or injectable 
DPP-4 inhibitor (sitagliptin, saxagliptin); number (%)
NA 8 (16.7)
Three tablets (metformin + vildagliptin + pioglitazone or 
metformin + vildagliptin + glimepiride); or two tablets 
(metformin + glimeripide) + injectable DPP-4 inhibitor (sitagliptin); 
number (%)
NA 4 (8.3)
Injectable insulin (±tablets: metformin + sitagliptin); number (%) NA 3 (6.3)
Multiple injections of insulin; number (%) NA 3 (6.3)
Table 2. Characteristics of control individuals (CT) and patients (T2D) included in the study. *Risk factors 
associated with higher risk of T2D, included: (i) BMI >25, (ii) prior history of gestational diabetes, (iii) 
hypertension, (iv) dyslipidemia, (v) cardiovascular disease, or vi) first-degree family member with T2D2. †BMI was 
calculated as weight (kg) divided by the square of height (m2). ‡Central obesity was regarded if waist circumference 
was ≥102 cm (40 in) in men or ≥88 cm (35 in) in women. §Hypertension was regarded if blood pressure was 
≥130/85 mm Hg (or receiving drug therapy for hypertension); ‖Hyperlipidemia (defined by the Adult Treatment 
Panel III of the National Cholesterol Education Program53. ¶Metabolic syndrome was diagnosed according to 
the NCEP-ATP III report54 requiring at least 3 of the following 5 conditions: (i) fasting glucose ≥100 mg/dL 
(or receiving drug therapy for hyperglycemia), (ii) blood pressure ≥130/85 mm Hg (or receiving drug therapy 
for hypertension), (iii) triglycerides ≥150 mg/dL (or receiving drug therapy for hypertriglyceridemia), (iii) 
HDL-C <40 mg/dL in men or <50 mg/dL in women (or receiving drug therapy for reduced HDL-C), (iv) waist 
circumference ≥102 cm (40 in) in men or ≥88 cm (35 in) in women. NA: not applicable.
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Gene/Variant
RQ levels, median (range) Statistical significance, p
CTTOTAL (n = 40)
CTRF− 
(n = 17) CTRF+ (n = 23) T2D (n = 48)
CTTOTAL 
vs. T2D
CTRF− vs. 
T2D
CTRF+ 
vs. T2D
CTRF− vs. 
CTRF+
Linear trend following the 
CTRF− → CTRF+ → T2D order
Genes of interest (total variants)
ADAMTS9 NE NE NE NE NA NA NA NA NA
CAMK1D 29.82  (9.467–61.03)
30.24  
(21.71–61.03)
29.27  
(9.467–49.79)
33.66  
(15.99–52.76) 0.9142 0.8178 0.7229 0.4455 0.907
CAPN10 2.784  (0.968–5.987)
2.785  
(2.199–5.987)
2.783  
(0.968–5.721)
2.699  
(1.026–5.384) 0.4390 0.1306 0.9116 0.2881 0.193
CDC123 4.859  (2.959–6.831)
4.808  
(3.196–6.019)
4.937  
(2.959–6.831)
4.909  
(3.069–11.59) 0.1160 0.2612 0.1711 0.9086 0.135
CDK5 0.945  (0.512–2.473)
0.919  
(0.625–2.473)
1.005  
(0.512–1.998)
1.151  
(0.600–8.103) 0.0056 0.0263 0.0264 0.9943 0.009
CDKAL1 4.311  (0.934–6.972)
4.544  
(2.545–6.440)
4.214  
(0.934–6.972)
3.733  
(0.652–8.709) 0.3256 0.1688 0.7639 0.3135 0.238
CDKN2A 0.655  (0.150–2.420)
0.426  
(0.200–2.220)
0.920  
(0.150–2.420)
0.910  
(0.320–4.030) 0.0411 0.0032 NS 0.0385 0.010
CDKN2B 0.596  (0.198–1.376)
0.576  
(0.379–1.376)
0.615  
(0.198–1.018)
0.652  
(0.155–1.819) 0.2766 0.4521 0.3519 0.9112 0.230
FTO 1.583  (0.641–2.559)
1.432  
(0.734–2.352)
1.780  
(0.641–2.559)
1.512  
(0.320–2.638) 0.3015 0.9741 0.1235 0.2506 0.626
HHEX 20.25  (5.30–37.23)
20.00  
(5.300–37.23)
20.25  
(5.30–33.41)
23.50  
(5.300–45.59) 0.1802 0.3541 0.2340 0.8076 0.145
HNF1B NE NE NE NE NA NA NA NA NA
HNF4A NE NE NE NE NA NA NA NA NA
IGF2BP2 3.139  (0.443–12.57)
3.670  
(1.568–5.501)
3.100  
(0.443–12.57)
3.671  
(0.777–20.09) 0.2438 0.4521 0.3046 0.8953 0.143
JAZF1 197.9  (12.46–688.8)
214.9  
(45.36–688.8)
182.4  
(12.46–498.3)
173.9  
(6.230–549.2) 0.7540 0.8944 0.6639 0.6765 0.956
KCNJ11 0.536  (0.010–15.50)
0.338  
(0.010–15.50)
0.568  
(0.010–11.01)
0.466  
(0.010–43.85) 0.6220 0.1509 0.6551 0.9618 0.605
KCNQ1 8.939  (2.083–15.48)
9.363  
(5.344–12.15)
8.431  
(2.083–15.48)
7.760  
(1.040–15.07) 0.2640 0.1509 0.6551 0.3687 0.191
MTNR1B NE NE NE NE NA NA NA NA NA
NOTCH2 5.228  (0.710–9.706)
5.303  
(0.710–9.706)
5.153  
(0.710–9.069)
4.859  
(0.710–11.94) 0.5411 0,5588 0,6850 0.9353 0.640
PPARG 0.01533  (0.0012–0.0361)
0.01540  
(0.0012–
0.0279)
0.01520  
(0.0012–0.0361)
0.01475  
(0.0012–0.0738) 0.8397 0.8562 0.8860 0.9622 0.856
SLC30A8 5.094  (0.0–695.4)
20.48  
(1.001–695.4)
3.075  
(0.0–364.0)
6.099  
(0.0–3139) 0.3922 0.5728 0.1908 0.1574 0.796
TCF7L2 3.803  (0.911–8.146)
3.678  
(1.942–8.146)
3.827  
(0.911–7.488)
3.782  
(1.673–10.13) 0.6388 0.6860 0.7138 0.7475 0.507
THADA 1.867  (0.592–4.052)
1.542  
(0.592–3.985)
1.951  
(0.817–4.052)
1.788  
(0.362–3.962) 0.8096 0.6147 0.8160 0.7117 0.602
TSPAN8 0.1590  (0.0247–1.132)
0.1071  
(0.0247–
1.132)
0.1894  
(0.0741–0.832)
0.2340  
(0.0398–2.124) 0.0055 0.0007 0.1889 0.0057 0.001
WFS1 0.2015  (0.0362–0.4887)
0.2193  
(0.0362–
0.4887)
0.1861  
(0.0842–0.3805)
0.2235  
(0.0388–0.4155) 0.2984 0.8687 0.1603 0.3743 0.465
Transcript variants of interest
CAPN10 tv3 3.924  (0.313–12.30)
5.098  
(1.016–12.30)
3.405  
(0.313–8.056)
2.208  
(0.313–12.43) 0.0004 <0.0001 0.0521 0.0655 <0.0005
CDK5 tv1 0.745  (0.285–2.266)
0.754  
(0.509–2.266)
0.735  
(0.285–1.441)
0.943  
(0.494–8.233) 0.0034 0.0206 0.0177 0.8196 0.006
CDK5 tv2 1.117  (0.453–2.938)
1.190  
(0.788–2.938)
1.071  
(0.453–2.139)
1.308  
(0.631–3.843) 0.0367 0.3732 0.0196 0.2098 0.167
CDKN2A tv1 NE NE NE NE NA NA NA NA NA
CDKN2A tv3 0.0300  (0.0062–2.083)
0.0145  
(0.0062–
2.083)
0.0390  
(0.0094–0.820)
0.0722  
(0.0062–3.481) 0.0035 0.0022 0.0770 0.0579 0.002
CDKN2A tv4 0.669  (0.321–2.600)
0.570  
(0.321–2.600)
0.850  
(0.360–1.489)
0.928  
(0.292–3.300) 0.0125 0.0002 0.4922 0.0151 0.001
CDKN2A tv5 NE NE NE NE NA NA NA NA NA
IGF2BP2 tv4 NE NE NE NE NA NA NA NA NA
Continued
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Differential expression of certain transcript variants in T2D patients versus CT controls. After 
collecting together data from both the qPCR and RNA-Seq assays, we further evaluated in the total cohort of the 
study (48 T2D patients and 40 controls): (i) the levels of individual transcript variants of the genes found to be dif-
ferentially expressed by qPCR (CDK5, CDKN2A, TSPAN8; Table 3 and Fig. 1A) and (ii) the levels of certain tran-
script variants found to be differentially expressed in RNA-Seq experiments (Fig. 1B and Supplemental Table 2). 
These transcript variants (tv) were the: NM_023085 (CAPN10 tv3), NM_004935.3 and NM_001164410.2 
(CDK5 tv1 and 2, respectively), NM_000077.4; p16INK4A, NM_058197.4, NM_058195.3; p14ARF, and 
NM_001195132.1 (CDKN2A tv1, 3, 4 & 5, respectively), NM_001291872, NM_001291873 and NM_001291875 
(IGF2BP2 tv4, 5 and 7, respectively), NM_000218 (KCNQ1 tv1), TCF7L2 tv4, 9 and 12 (NM_001146284, 
NM_001198527 and NM_001198530, respectively), NM_022065, NM_001083953, NM_001271643 and 
NM_001271644 (THADA tv1, 3, 4 and 5, respectively). The CDKAL1 and TSPAN8 genes, which have only one 
tv each (NM_017774 and NM_004616.2, respectively) were studied in the series of qPCR experiments described 
above. The NR_073394 non-coding tv of the THADA gene, was not selected to be further studied.
The levels (median; range) of the transcript variants in patient and control groups are reported in Table 3. 
Αs attested by Mann-Whitney U test, compared to controls, T2D patients expressed lower levels of CAPN10 
tv3 [p = 0.0004, RQ levels (median; range) for T2D = 2.208 (0.313–12.43) and for CT = 3.924 (0.313–12.30), 
fold-change T2D vs. CT = 0.56] and of KCNQ1 tv1 [p = 0.0761, RQ levels (median; range) for T2D = 8.456 
(2.880–16.93) and for CT = 9.408 (2.445–18.34), fold-change T2D vs. CT = 0.89] (Table 3 and Fig. 1C; upper 
row). Jonckheere-Terpstra test strongly supported these findings by revealing a significant gradual decrease 
among the CTRF−, CTRF+ and T2D groups in the levels of CAPN10 tv3 [p < 0.0005, RQ levels (median; range) for 
CTRF− = 5.098 (1.016–12.30), for CTRF+ = 3.405 (0.313–8.056), for T2D = 2.208 (0.313–12.43), fold-change for 
CTRF+ vs. CTRF− = 0.67 and for T2D vs. CTRF+ = 0.65] and KCNQ1 tv1 [p = 0.013, RQ levels (median; range) for 
CTRF− = 10.520 (7.504–18.34), for CTRF+ = 8.951 (2.445–16.34) and for T2D = 8.456 (2.880–16.93), fold-change 
for CTRF+ vs. CTRF− = 0.85 and for T2D vs. CTRF+ = 0.95] (Table 3 and Fig. 1C; lower row). On the other hand, 
compared to controls, patients exhibited higher levels of CDK5 tv1 [p = 0.0034, RQ levels (median; range) for 
T2D = 0.943 (0.494–8.233) and for CT = 0.745 (0.285–2.266), fold-change T2D vs. CT = 1.27], of CDKN2A tv3 
[p = 0.0035, RQ levels (median; range) for T2D = 0.0722 (0.0062–3.481) and for CT = 0.0300 (0.0062–2.083), 
fold-change T2D vs. CT = 2.41), of CDKN2A tv4 (p = 0.0125, RQ levels (median; range) for T2D = 0.928 (0.292–
3.300) and for CT = 0.669 (0.321–2.600), fold-change T2D vs. CT = 1.39) and of IGF2BP2 tv7 (p = 0.22, RQ levels 
(median; range) for T2D = 4.485 (1.032–14.14) and for CT = 3.903 (0.516–12.14), fold-change T2D vs. CT = 1.15) 
(Table 3 and Fig. 1C; upper row). Also, a significant gradual increase in the levels of these transcripts was observed 
among the groups of CTRF−, CTRF+ and T2D patients [for CDK5 tv1: p = 0.006, RQ levels (median; range) for 
CTRF− = 0.754 (0.509–2.266), for CTRF+ = 0.735 (0.285–1.441) and for T2D = 0.943 (0.494–8.233), fold-change 
CTRF+ vs. CTRF− = 0.97 and for T2D vs. CTRF+ = 1.28; for CDKN2A tv3: p = 0.002, RQ levels (median; range) 
for CTRF− = 0.0145 (0.0062–2.083), for CTRF+ = 0.0390 (0.0094–0.820) and for T2D = 0.0722 (0.0062–3.481), 
fold-change for CTRF+ vs. CTRF− = 2.67 and for T2D vs. CTRF+ = 1.85; for CDKN2A tv4: p = 0.001, RQ levels 
(median; range) for CTRF− = 0.570 (0.321–2.600), for CTRF+ = 0.850 (0.360–1.489) and for T2D = 0.928 (0.292–
3.300), fold-change for CTRF+ vs. CTRF− = 1.49 and for T2D vs. CTRF+ = 1.09; for IGF2BP2 tv7: p = 0.050, RQ 
levels (median; range) for CTRF− = 3.670 (1.4040–12.14), for CTRF+ = 3.989 (0.5160–11.91) and for T2D = 4.485 
(1.032–14.14), fold-change for CTRF+ vs. CTRF− = 1.09 and for T2D vs. CTRF+ = 1.12) (Table 3 and Fig. 1C; lower 
row).
Gene/Variant
RQ levels, median (range) Statistical significance, p
CTTOTAL (n = 40)
CTRF− 
(n = 17) CTRF+ (n = 23) T2D (n = 48)
CTTOTAL 
vs. T2D
CTRF− vs. 
T2D
CTRF+ 
vs. T2D
CTRF− vs. 
CTRF+
Linear trend following the 
CTRF− → CTRF+ → T2D order
IGF2BP2 tv4, 5, 
6 & 7
0.0106  
(0.0106–0.4114)
0.0106  
(0.0106–
0.3017)
0.0106  
(0.0106–0.4114)
0.0106  
(0.0106–0.9255) 0.8008 0.8537 0.5898 0.6346 0.970
IGF2BP2 tv7 3.903  (0.5160–12.14)
3.670  
(1.4040–
12.14)
3.989  
(0.5160–11.91)
4.485  
(1.032–14.14) 0.2167 0.1665 0.2076 0.5629 0.050
KCNQ1 tv1 9.408  (2.445–18.34)
10.520  
(7.504–18.34)
8.951  
(2.445–16.34)
8.456  
(2.880–16.93) 0.0761 0.0143 0.5530 0.0448 0.013
TCF7L2 tv4 & 9 1.478  (0.842–3.843)
1.773  
(0.842–3.843)
1.476  
(1.087–3.190)
1.392  
(0.396–4.554) 0.4641 0.6832 0.5051 0.8466 0.567
TCF7L2 tv12 3.036  (0.247–7.023)
3.315  
(1.434–6.988)
2.808  
(0.247–7.023)
3.490  
(0.494–7.614) 0.7903 0.3856 0.2659 0.1558 0.945
THADA tv1 & 3 2.513  (1.256–5.316)
2.736  
(1.559–4.599)
2.126  
(1.256–5.316)
2.326  
(1.008–7.321) 0.5999 0.1509 0.6596 0.1302 0.382
THADA tv4 2.319  (0.916–6.221)
2.241  
(1.519–6.221)
2.397  
(0.916–4.080)
2.464  
(0.912–8.510) 0.4336 0.9741 0.2606 0.4618 0.549
THADA tv5 2.582  (0.596–35.83)
2.933  
(1.128–35.83)
2.304  
(0.596–16.01)
3.452  
(0.718–120.7) 0.0479 0.0237 0.0341 0.3544 0.129
Table 3. Relative quantification (RQ) expression levels of total variants of the 24 genes-of-interest and of their 
specific transcript variants. Data are expressed as median values (range). The between-group up- or down-
regulation and the CTRF− → CTRF+ → T2D-ordered linear trend were evaluated by Mann-Whitney U and 
Jonckheere-Terpstra non-parametric tests, respectively.
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Figure 1. (A) Dot-plots depicting the differential distribution of mRNA levels (RQ units) of CDK5, CDKN2A 
and TSPAN8 in controls (CT) and T2D patients (T2D) (upper row of panels), as well as among controls 
without T2D risk factors (CTRF−), controls with T2D risk factors (CTRF+) and T2D patients (lower row of 
panels), as attested by appropriate non-parametric tests. Mann-Whitney analysis revealed that T2D patients 
are characterized by higher mRNA levels of CDK5, CDKN2A and TSPAN8, compared to controls (upper 
row). Jonckheere-Terpstra test showed a stepwise increase in the total mRNA levels of the abovementioned 
genes among the CTRF−, CTRF+ and T2D groups (lower row). P-values are designated by asterisks (*p < 0.05, 
**p < 0.01, ***p < 0.001), whereas horizontal bars represent the median value of the group (B). Area-
proportional Euler diagrams showing the differentially expressed genes and transcripts variants between 
the samples of controls (CT) and T2D patients (T2D), as analysed by RNA-seq. a. Diagrams representing 
the differentially expressed genes between T2D patients and controls, within the total 24 genes-of-interest 
(T2D-susceptibility genes; grey circle). Based on our data, T2D patients expressed exclusively higher levels 
of total mRNA of 3 genes (namely CAPN10, KCNQ1, TCF7L2) and lower levels of total mRNA of 2 genes 
(namely CDKAL1 and IGF2BP2), compared to controls, while mRNA expression of one gene (THADA) 
was found to be either up- or- downregulated in T2D versus CT groups. Further analysis of the individual 
gene-transcript variants revealed that the levels of 6 out of the 77 transcript variants of interest [NM_023085 
(CAPN10), NM_000218 (KCNQ1), NM_001198530, NM_001146284, NM_001198527 (all of TCF7L2), 
NR_073394 (THADA)] were increased, while 8 [NM_017774 (CDKAL1), NM_001291873, NM_001291872, 
NM_001291875 (all of IGF2BP2), NM_001271643, NM_001271644, NM_001083953, NM_022065 (all of 
THADA)] decreased in patients versus controls. Differential expression was considered as fold-change of the 
relative expression levels (mean of reads per kilobase million, RPKM) between the two groups (CT:T2D ratio) 
<0.5 or >2. (C) Dot-plots depicting the differential distribution of mRNA levels (RQ units) of CAPN10 tv3, 
CDK5 tv1, CDKN2A tv3, CDKN2A tv4, IGF2BP2 tv7, KCNQ1 tv1 and TSPAN8 in controls (CT) and T2D 
patients (T2D) (upper row of panels), as well as among controls without T2D risk factors (CTRF−), controls with 
T2D risk factors (CTRF+) and T2D patients (lower row of panels), as attested by appropriate non-parametric 
tests. Mann-Whitney analysis revealed that T2D patients are characterized by higher mRNA levels of CDK5 
tv1, CDKN2A tv3, CDKN2A tv4, IGF2BP2 tv7, and TSPAN8, while lower levels of CAPN10 tv3 and KCNQ1 tv1, 
compared to controls (upper row). Jonckheere-Terpstra test showed that the mRNA levels’ distribution of the 
abovementioned transcripts followed a linear trend among the CTRF−, CTRF+ and T2D groups: increase in the 
cases of CDK5 tv1, CDKN2A tv3, CDKN2A tv4, IGF2BP2 tv7, and TSPAN8 and decrease in the cases of CAPN10 
tv3 and KCNQ1 tv1 (lower row). P-values are designated by asterisks (*p < 0.05, **p < 0.01, ***p < 0.001), 
whereas horizontal bars represent the median value of the group; D. Dot-plots depicting the differential 
distribution of mRNA levels (RQ units) of CDK5 tv2 and THADA tv5 in controls (CT) and T2D patients (T2D) 
(upper row of panels), as well as among controls without T2D risk factors (CTRF−), controls with T2D risk factors 
(CTRF+) and T2D patients (lower row of panels), as attested by appropriate non-parametric tests. Mann-Whitney 
analysis revealed that T2D patients are characterized by higher mRNA levels of CDK5 tv2 and THADA tv5 
(upper row). More specifically, there is a significant difference of these tv levels between T2D individuals and the 
group of controls with T2D risk factors (CTRF+), while not with the controls without such factors (lower row). P-
values are designated by asterisks (*p < 0.05), whereas horizontal bars represent the median value of the group.
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A different distribution pattern was detected in the case of CDK5 tv2 and THADA tv5: T2D patients expressed 
elevated levels compared to controls [for CDK5 tv2: p = 0.0367, RQ levels (median; range) for T2D = 1.308 
(0.631–3.843) and for CT = 1.117 (0.453–2.938), fold-change T2D vs. CT = 1.17; for THADA tv5: p = 0.0479, 
RQ levels (median; range) for T2D = 3.452 (0.718–120.7) and for CT = 2.582 (0.596–35.83), fold-change = 1.34) 
(Table 3 and Fig. 1D; upper row), though, the lowest levels were detected in CTRF+ individuals and interme-
diate values in CTRF− subjects [for CDK5 tv2: RQ levels (median; range) for CTRF− = 1.190 (0.788–2.938), for 
CTRF+ = 1.071 (0.453–2.139) and for T2D = 1.308 (0.631–3.843), fold-change for CTRF+ vs. CTRF− = 0.90 and 
for T2D vs. CTRF+ = 1.22; for THADA tv5: RQ levels (median; range) for CTRF− = 2.933 (1.128–35.83), for 
CTRF+ = 2.304 (0.596–16.01) and for T2D = 3.452 (0.718–120.7), fold-change CTRF+ vs. CTRF− = 0.79 and for 
T2D vs. CTRF+ = 1.50] (Table 3 and Fig. 1D; lower row).
Moreover, correction for multiple comparisons revealed statistically significant differences in the levels of 
CAPN10 tv3, CDK5 tv1, CDK5 tv2, CDKN2A tv3, CDKN2A tv4, and THADA tv5 between controls and T2D 
patients, and of CAPN10 tv3, CDK5 tv1, CDKN2A tv3, CDKN2A tv4, IGF2BP2 tv7, KCNQ1 tv1 among CTRF−, 
CTRF+ and T2D subjects.
Based on the above findings, the panel of the T2D-specific transcript variants finally included the: CAPN10 
tv3, CDK5 tv1, CDK5 tv2, CDKN2A tv3, CDKN2A tv4, IGF2BP2 tv7, KCNQ1 tv1, THADA tv5 and TSPAN8. 
Among them, binomial multivariate analysis corrected for age and sex revealed that CAPN10 tv3 can predict T2D 
among participants of the current study (p = 0.022, OR = 0.726). A schematic representation of the T2D-specific 
transcript variants, also in comparison with the canonical transcript for each gene, is shown in Fig. 2.
Associations of mRNA levels with clinicopathological data. The levels of the T2D-specific tran-
scripts were found to associate with various clinicopathological parameters (Supplemental Table 3). Notably, the 
associations revealed were different in patient versus control groups.
In detail, CDK5 tv1 levels correlated positively with serum insulin (μU/ml) and glycated haemoglobin 
(HbA1c; % or mmol/mol) levels and negatively with hyperlipidemia in T2D patients, while positively with serum 
triglycerides levels (mg/dl) (p < 0.05) in CTRF+ subjects. As for the CDK5 tv2 levels, these also correlated strongly 
with serum insulin levels, and moreover with the presence of central obesity in the T2D group (p < 0.05).
The levels of CDKN2A tv3 were as well significantly associated with serum insulin levels in T2D patients 
(p < 0.01), while these of CDKN2A tv4 correlated positively with BMI and waist-to-hip ratio and negatively with 
serum HDL levels (mg/dl) in the CTRF+ subgroup (p < 0.05).
Serum insulin levels in T2D patients associated also with THADA tv5 (p < 0.01) and TSPAN8 levels (p < 0.05), 
tended to correlate negatively with KCNQ1 tv1 levels (p = 0.06), while, in CTRF+ subjects, associated with 
IGF2BP2 tv7 levels (p < 0.05). Additionally, in T2D individuals, the levels of THADA tv5 correlated reversely 
with hyperlipidemia and those of IGF2BP2 tv7 positively with BMI (p < 0.05). In CTRF+ individuals, mRNA lev-
els of TSPAN8 associated with T2D family history (p < 0.01), of IGF2BP2 tv7 with serum glucose levels, while in 
the total group of controls, KCNQ1 tv1 levels reversely with BMI, central obesity, glucose and LDL (mg/dl) levels 
(p < 0.05).
Furthermore, correction for multiple comparisons confirmed certain of the above correlations: a) In T2D 
subjects, serum insulin levels were associated with the levels of CDK5 tv1, CDK5 tv2, CDKN2A tv3, KCNQ1 tv1, 
THADA tv5 and TSPAN8, hyperlipidemia was associated with the levels of CDK5 tv1 and THADA tv5, and BMI 
with the levels of IGF2BP2 tv7; b) In control individuals, serum insulin levels were correlated with the levels of 
IGF2BP2 tv7, serum HDL levels, BMI, and waist-to-hip ratio with the levels of CDKN2A tv4, and family history 
of T2D with the levels of TSPAN8.
Various associations were also detected between clinicopathological data and the levels of transcripts which 
did not exhibit any differential distribution among the groups of patients and controls (data not shown).
Analysis of the tissue-specific expression pattern and eQTLs of the differentially expressed 
genes using public available datasets. Based on public available data of the GTEx portal19, the CAPN10, 
CDK5, CDKN2A, IGF2BP2, KCNQ1, THADA and TSPAN8 genes, as well as their transcript variants CDK5 
tv1, CDK5 tv2, IGF2BP2 tv7, KCNQ1 tv1 and THADA tv5, are expressed in a series of human tissues including 
blood and T2D-target tissues (adipose tissue, liver, skeletal muscle, pancreas) (Fig. 3). No data were available for 
CAPN10 tv3, CDKN2A tv3 and tv4.
Blood eQTL browser and GTEx portal were used for the analysis of eQTLs in the differentially expressed 
genes. For each one, a significant number of eQTLs appeared; however, we focused on eQTLs linked to 
T2D-related SNPs in blood or T2D-target tissues (Supplemental Table 4). Significant eQTLs related to T2D-SNPs 
were found on CAPN10, CDKN2A, IGF2BP2 and KCNQ1 in blood cells, and on CAPN10 and TSPAN8 in skeletal 
muscle. Affected genes are reported in Supplemental Table 4.
Also, CAPN10, the most significantly differentiated gene herein, is suggested to be an eGene (that is a gene 
having at least one cis-eQTL acting upon it), affected by several eQTLs on GPR35, RNPEPL1, and/or itself. 
Nevertheless, only the rs5030952-eQTL has a known (GWAS) association with T2D development (Supplemental 
Table 5).
Discussion
Despite numerous GWAS and other clinical studies revealing a large pool of SNPs associated with T2D, none of 
them has been yet proven promising for its diagnosis and/or prognosis5. Moreover, their causal relationship with 
T2D pathogenesis is not well-defined; epigenetic mechanisms can influence the expression of T2D-susceptibility 
genes, while DNA sequence itself alters the way the epigenome exerts its regulatory effect21–25. Furthermore, 
eQTLs associated with T2D-genetic variants may be also involved26. Herein, the expression profile of a panel of 
T2D-susceptibility genes, with special focus on their individual transcripts, was investigated in peripheral blood 
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of T2D patients and controls, utilizing a combination of high-throughput and highly-sensitive molecular meth-
odologies (RNA-Seq and qPCR).
Our data revealed a T2D-specific pattern of expression of nine transcript variants of the genes: CAPN10, 
CDK5, CDKN2A, IGF2BP2, KCNQ1, THADA and TSPAN8. Compared to controls, patients exhibited 
down-regulated levels of the tv3 of CAPN10 and tv1 of KCNQ1, while up-regulated levels of CDK5 tv1 and tv2, 
CDKN2A tv3 and tv4, IGF2BP2 tv7, THADA tv5 and TSPAN8. Publicly available datasets suggest that many 
human tissues including peripheral blood and T2D-target tissues express the abovementioned genes, allowing 
to postulate that the T2D-specific expression pattern found herein, may reflect pathogenetic mechanisms in 
disease-affected organs and/or peripheral blood14,15,19,20.
Among the down-regulated molecules is the tv3 of CAPN10. The gene encodes a protein implicated in glucose 
transporter 4 (GLUT4) translocation, insulin secretion, and apoptotic processes in pancreatic cells27. Compared 
to the canonical variant 1, tv3 lacks two consecutive exons, resulting in the loss of an in-frame segment in the 3’ 
coding region, and the encoded isoform (c) is shorter than isoform a (Fig. 2). The gene bears the rs3792267 and 
rs5030952 T2D-related SNPs3,16; however, tv3 does not bear any of them. Therefore, the decreased expression 
levels observed in patients, might be due to epigenetic and/or other transcriptional regulations24,25. It is worth 
mentioning that, herein, CAPN10 tv3 exhibited the highest association with the disease among all the deregulated 
molecules, as attested by both univariate and multivariate analysis. Yet, it is the only transcript which showed 
no association with any of the clinicopathological parameters tested, possibly indicating the highly complicated 
molecular networks underlying T2D.
The levels of the canonical transcript (tv1) of KCNQ1 (Fig. 2) were also decreased in the T2D group, while 
they were lower in the CTRF+ compared to the CTRF− group. ΚCNQ1 encodes the pore-forming subunit of a 
voltage-gated K+ channel (KvLQT1) that is essential for the repolarization phase of the action potential in cardiac 
muscle28. It is also expressed by pancreatic islets29, plays a key-role in the regulation of insulin secretion30 and its 
genetic variants have been associated with impaired insulin secretion in humans31,32. In these terms, the decreased 
expression of KCNQ1 tv1 in the CTRF+ and T2D groups observed in our study, and the reverse correlation with 
serum insulin levels, may indeed reflect the negative regulation on insulin secretory function exerted by KCNQ1 
in patients and pre-disposed individuals.
Figure 2. Detailed gene-structure of the transcript (splice) variants of CDK5, CDKN2A, CAPN10, IGF2BP2, 
KCNQ1, THADA and TSPAN8 that were found to be differentially expressed in T2D. Exons are presented as 
boxes and introns as lines. Grey and white boxes represent coding and non-coding exons, respectively. The 
numbers within the boxes and above the lines indicate exon’s or intron’s length in nucleotides (nt). Arrows (↓) 
and asterisks (*) indicate the positions of the ATG starting codon and the stop codon (TGA or TAA or TAG), 
respectively. In each gene, the canonical (classic) and the differentially expressed transcript variants in T2D 
patients, indicated by arrow (→) are depicted. For each transcript variant, the GenBank® accession number, as 
well as the protein isoform and length in amino acids (aa) are shown.
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Among the T2D-up-regulated molecules, there are both the two transcripts of CDK5 (Fig. 2). CDK5 is a 
serine/threonine protein kinase, involved in the degeneration of beta-cells and obstruction of insulin secretion 
through the generation of p35/CDK5 complexes33; its inhibition has been shown to protect these cells from gluco-
toxicity34. The overactivity of CDK5 and its activator p35 have been as well correlated with neuronal dysfunction 
in patients with Alzheimer’s disease (AD), and this could be one of the possible common mechanisms shared by 
these two degenerative disorders34. CDK5 is highly regulated by the T2D-susceptibility gene CDKAL117, through 
the rs7756992 SNP of the latter, which increases the risk for T2D35. Our data showed decreased levels of CDK5 tv1 
and 2 in T2D patients compared to controls; though they exhibited different distribution patterns and correlated 
with different clinicopathological parameters in the CTRF− versus CTRF+ groups, but both with increased serum 
insulin levels. This might be probably attributed to different transcriptional regulations and distinct pathogenetic 
mechanisms leading, however, to the same “pre-disease” phenotype. Moreover, it is reported that as tv1, the tv2 
Figure 3. Bar diagrams obtained from the GTEx portal (5/3/2018) depicting the expression pattern of the 
differentially expressed genes and transcript variants in various human tissues and cells. mRNA levels are 
expressed as transcripts per million (TPM). Boxes represent the median (range) of the normalized values. Boxes 
corresponding to whole blood or T2D-affected tissues are grey-colored highlighted.
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of CDK5, in which an in-frame coding exon is skipped36 (Fig. 2), is also a negative regulator of Wnt/β-catenin 
signalling, a pathway involved in T2D development37.
SNPs in the CDKN2A/B locus were recently implicated in the negative regulation of beta-cell mass, prolifera-
tion and insulin secretory function, as well as in metabolic processes in adipose tissue, liver and muscles22. Also, 
in human islets, this locus is affected by epigenetic factors38, however, no effect on gene expression is known22. 
CDKN2A/B variants affect also the risk for cardiovascular disease39 and cancer40, and this could be a link for 
the common pathogenetic mechanisms shared with T2D41. Additionally, in blood, T2D-associated SNPs on 
CDKN2A are eQTLs which affect the expression of PSEN119 involved in AD and cancer42,43, connecting possibly 
these three morbidities. In this study, T2D patients expressed elevated levels of CDKN2A, and specifically of 
CDKN2A tv3 and 4: the first one highly associated with serum insulin levels in patients, and the second one with 
certain T2D-risk factors in controls. This may suggest their differential implication in disease development and/
or progress. However, tv3 contains an alternative open reading frame (Fig. 2) and it is specifically expressed in the 
pancreas44. CDKN2A tv4 has a distinct first, but shares a common second exon with the canonical tv1, translated 
in different reading frames (Fig. 2): the encoded protein (p14ARF) lacks sequence similarity to the classic isoform 
(p16INK4a), and it is known to be nucleoplasmic but also recruited to mitochondria45. These characteristics may 
suggest tv-specific functions, possibly implicated in disease’s pathogenesis.
IGF2BP2 binds the 5′ UTR of the insulin-like growth factor 2 mRNA and regulates its translation16. Moreover, 
T2D-related SNPs on IGF2BP2 are eQTLs affecting SENP2, a gene crucially involved in adipogenesis and T2D 
development46. Herein, the levels of the tv7 of IGF2BP2 (which lacks exons 1 and 2 compared to the canonical 
tv1) exhibited a significant stepwise up-regulation from CTRF− to CTRF+ and to T2D individuals. Their correlation 
with BMI in patients, and serum glucose and insulin levels in CTRF+ cases, indicates its functional involvement 
in T2D pathogenesis.
Patients exhibited also elevated levels of TSPAN8 (only one known tv) and of THADA tv5 (with alternative 3′ 
coding region and 3′ UTR, encoding a shorter isoform (c) with a distinct C-terminus) (Fig. 2). The first gene is 
regarded as a prognostic factor and potential therapeutic target for certain human carcinomas47–50, while chro-
mosomal aberrations of the second are observed in benign thyroid adenomas51. They both bear SNPs associated 
with T2D, though there is no knowledge regarding their involvement in its development3,16. Herein, the correla-
tion of their levels with T2D, certain parameters and/or risk factors provides the first evidence for their possible 
implication in T2D pathogenesis.
The levels of TCF7L2, the most highly-related T2D-susceptibility gene, as well as of other T2D-susceptibility 
genes, were comparable between patients and controls; however, they correlated with certain disease characteris-
tics or risk factors, supporting their implication in T2D development.
However, certain limitations of this study need to be considered: (a) the fact that not all the known 
T2D-susceptibilty genes are examined, (b) the relatively small number of participants and RNA-seq samples 
tested; the latter was overcome by the subsequent qPCR validation of the proposed deregulated transcript var-
iants, discriminating between the true- and false-positive results, though, RNA-seq false-negative results could 
not been ruled out, (c) no paired-analysis of both the transcript levels and the presence of T2D-related SNPs was 
conducted; search throughout the Blood eQTL browser and the GTEx portal served only as a guide for their 
association and does not adequately explore the genetic determinants of the gene-expression variation, (d) the 
significant difference in the median age of patients and controls tested (Table 2); age associates with epigenetic 
changes52, thus it cannot be excluded as possible factor influencing the gene-expression variations observed in our 
cohort. However, after binomial multivariate analysis corrected for age and sex, CAPN10 tv3 still remain capable 
to predict T2D.
Nevertheless, by analyzing the expression patterns of a panel of the most highly-associated T2D-susceptibility 
genes, the current study offers suggestive data on the deregulated levels of certain transcript variants. Future 
research is required to elucidate their involvement in principal molecular and biochemical networks underlying 
T2D pathogenesis. Also, large-scale perspective clinical studies are needed to evaluate their potential to serve as 
possible biomarkers for its diagnosis, prognosis and/or monitoring.
Data Availability
The RNA-seq and qPCR raw data used to support the findings of this study are available from the corresponding 
author upon request.
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